Fundraising Fox

Tagworks Pharmaceuticals

Nijmegen, NL · Founded 2011 · 44 employees on LinkedIn · 9 known investors

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target. Its lead program targets TAG72, a non-internalizing marker expressed in difficult-to-treat solid tumors, aiming to expand ADC target scope and therapeutic window.

BiotechHealthtechMedical Devices

Investors · 9

BifHamburg
Lightstone VenturesPortola Valley
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Novartis Venture FundBasel · $5M – $25M
Ysios CapitalBarcelona · $5.4M – $21.6M
Gilde Healthcarereported · 2 sourcesUtrecht · $1.1M – $55M
Oost NLreportedApeldoorn · $108K – $5.4M

Also in the syndicate · 2

MeneldorNovartis' venture arm

Funding

SEC filings, press & company announcements

$65M disclosed across 1 round · 2023

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap
Zymeworks9 shared keywordsZymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D. It operates as a royalty-driven organization that builds and manages a portfolio of healthcare assets through partnerships and collaborations across multiple therapeutic areas.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Springworkstx6 shared keywordsSpringWorks is a biopharmaceutical company developing targeted oncology and rare disease therapies, including its gamma secretase inhibitor nirogacestat being evaluated in BCMA combination regimens for multiple myeloma. It focuses on late-stage rare oncology programs for patients with severe rare diseases and cancers.

Companies competing with Tagworks Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Philips spin-off raises $64 million for click-to-release drugscen.acs.org · Jun 2023Tagworks Pharmaceuticals Raises $65M in Series A Financingfinsmes.com · Jun 2023Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeuticsprnewswire.com · Jun 2023Startup Tagworks raises $65M to make ‘click-to-release’ cancer drugs | BioPharma Divebiopharmadive.com · Jun 2023

Frequently asked questions

What does Tagworks Pharmaceuticals do?
Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target. Its lead program targets TAG72, a non-internalizing marker expressed in difficult-to-treat solid tumors, aiming to expand ADC target scope and therapeutic window.
Who are Tagworks Pharmaceuticals's investors?
Tagworks Pharmaceuticals's investors include Bif, Lightstone Ventures, New Enterprise Associates (NEA), Novartis Venture Fund, Ysios Capital, Gilde Healthcare, Oost NL.
How much funding has Tagworks Pharmaceuticals raised?
Tagworks Pharmaceuticals has disclosed $65M raised across 1 round.
Where is Tagworks Pharmaceuticals headquartered?
Tagworks Pharmaceuticals is headquartered in Nijmegen, NL.